201 related articles for article (PubMed ID: 25963741)
1. Thymosin-β4 is a determinant of drug sensitivity for Fenretinide and Vorinostat combination therapy in neuroblastoma.
Cheung BB; Tan O; Koach J; Liu B; Shum MS; Carter DR; Sutton S; Po'uha ST; Chesler L; Haber M; Norris MD; Kavallaris M; Liu T; O'Neill GM; Marshall GM
Mol Oncol; 2015 Aug; 9(7):1484-500. PubMed ID: 25963741
[TBL] [Abstract][Full Text] [Related]
2. Fenretinide-induced caspase-8 activation and apoptosis in an established model of metastatic neuroblastoma.
Raguénez G; Mühlethaler-Mottet A; Meier R; Duros C; Bénard J; Gross N
BMC Cancer; 2009 Mar; 9():97. PubMed ID: 19331667
[TBL] [Abstract][Full Text] [Related]
3. 4-oxo-fenretinide, a recently identified fenretinide metabolite, induces marked G2-M cell cycle arrest and apoptosis in fenretinide-sensitive and fenretinide-resistant cell lines.
Villani MG; Appierto V; Cavadini E; Bettiga A; Prinetti A; Clagett-Dame M; Curley RW; Formelli F
Cancer Res; 2006 Mar; 66(6):3238-47. PubMed ID: 16540676
[TBL] [Abstract][Full Text] [Related]
4. P450 inhibitor ketoconazole increased the intratumor drug levels and antitumor activity of fenretinide in human neuroblastoma xenograft models.
Lopez-Barcons L; Maurer BJ; Kang MH; Reynolds CP
Int J Cancer; 2017 Jul; 141(2):405-413. PubMed ID: 28340497
[TBL] [Abstract][Full Text] [Related]
5. Fenretinide sensitizes multidrug-resistant human neuroblastoma cells to antibody-independent and ch14.18-mediated NK cell cytotoxicity.
Shibina A; Seidel D; Somanchi SS; Lee DA; Stermann A; Maurer BJ; Lode HN; Reynolds CP; Huebener N
J Mol Med (Berl); 2013 Apr; 91(4):459-72. PubMed ID: 23052481
[TBL] [Abstract][Full Text] [Related]
6. Synergistic activity of fenretinide and the Bcl-2 family protein inhibitor ABT-737 against human neuroblastoma.
Fang H; Harned TM; Kalous O; Maldonado V; DeClerck YA; Reynolds CP
Clin Cancer Res; 2011 Nov; 17(22):7093-104. PubMed ID: 21933888
[TBL] [Abstract][Full Text] [Related]
7. Reactive Oxygen Species Mediates the Synergistic Activity of Fenretinide Combined with the Microtubule Inhibitor ABT-751 against Multidrug-Resistant Recurrent Neuroblastoma Xenografts.
Chen NE; Maldonado NV; Khankaldyyan V; Shimada H; Song MM; Maurer BJ; Reynolds CP
Mol Cancer Ther; 2016 Nov; 15(11):2653-2664. PubMed ID: 27530131
[TBL] [Abstract][Full Text] [Related]
8. Synergistic induction of apoptosis of neuroblastoma by fenretinide or CD437 in combination with chemotherapeutic drugs.
Lovat PE; Ranalli M; Bernassola F; Tilby M; Malcolm AJ; Pearson AD; Piacentini M; Melino G; Redfern CP
Int J Cancer; 2000 Dec; 88(6):977-85. PubMed ID: 11093824
[TBL] [Abstract][Full Text] [Related]
9. Response of preclinical medulloblastoma models to combination therapy with 13-cis retinoic acid and suberoylanilide hydroxamic acid (SAHA).
Spiller SE; Ditzler SH; Pullar BJ; Olson JM
J Neurooncol; 2008 Apr; 87(2):133-41. PubMed ID: 18060600
[TBL] [Abstract][Full Text] [Related]
10. In vitro and in vivo antitumor activity of liposomal Fenretinide targeted to human neuroblastoma.
Raffaghello L; Pagnan G; Pastorino F; Cosimo E; Brignole C; Marimpietri D; Montaldo PG; Gambini C; Allen TM; Bogenmann E; Ponzoni M
Int J Cancer; 2003 May; 104(5):559-67. PubMed ID: 12594810
[TBL] [Abstract][Full Text] [Related]
11. Immunoliposomal fenretinide: a novel antitumoral drug for human neuroblastoma.
Raffaghello L; Pagnan G; Pastorino F; Cosimo E; Brignole C; Marimpietri D; Bogenmann E; Ponzoni M; Montaldo PG
Cancer Lett; 2003 Jul; 197(1-2):151-5. PubMed ID: 12880975
[TBL] [Abstract][Full Text] [Related]
12. Efficacy of class I and II vs class III histone deacetylase inhibitors in neuroblastoma.
Lautz TB; Naiditch JA; Clark S; Chu F; Madonna MB
J Pediatr Surg; 2012 Jun; 47(6):1267-71. PubMed ID: 22703804
[TBL] [Abstract][Full Text] [Related]
13. The histone deacetylase inhibitor SAHA acts in synergism with fenretinide and doxorubicin to control growth of rhabdoid tumor cells.
Kerl K; Ries D; Unland R; Borchert C; Moreno N; Hasselblatt M; Jürgens H; Kool M; Görlich D; Eveslage M; Jung M; Meisterernst M; Frühwald M
BMC Cancer; 2013 Jun; 13():286. PubMed ID: 23764045
[TBL] [Abstract][Full Text] [Related]
14. Suberoylanilide hydroxamic acid increases anti-cancer effect of tumor necrosis factor-α through up-regulation of TNF receptor 1 in lung cancer cells.
You BR; Han BR; Park WH
Oncotarget; 2017 Mar; 8(11):17726-17737. PubMed ID: 28099148
[TBL] [Abstract][Full Text] [Related]
15. Enhanced anti-tumor and anti-angiogenic efficacy of a novel liposomal fenretinide on human neuroblastoma.
Di Paolo D; Pastorino F; Zuccari G; Caffa I; Loi M; Marimpietri D; Brignole C; Perri P; Cilli M; Nico B; Ribatti D; Pistoia V; Ponzoni M; Pagnan G
J Control Release; 2013 Sep; 170(3):445-51. PubMed ID: 23792118
[TBL] [Abstract][Full Text] [Related]
16. Histone deacetylase inhibitor, suberoylanilide hydroxamic acid (Vorinostat, SAHA) profoundly inhibits the growth of human pancreatic cancer cells.
Kumagai T; Wakimoto N; Yin D; Gery S; Kawamata N; Takai N; Komatsu N; Chumakov A; Imai Y; Koeffler HP
Int J Cancer; 2007 Aug; 121(3):656-65. PubMed ID: 17417771
[TBL] [Abstract][Full Text] [Related]
17. ING5-mediated antineuroblastoma effects of suberoylanilide hydroxamic acid.
Wu JC; Jiang HM; Yang XH; Zheng HC
Cancer Med; 2018 Sep; 7(9):4554-4569. PubMed ID: 30091530
[TBL] [Abstract][Full Text] [Related]
18. p75 neurotrophin receptor and fenretinide-induced signaling in neuroblastoma.
Ganeshan VR; Schor NF
Cancer Chemother Pharmacol; 2014 Feb; 73(2):271-9. PubMed ID: 24253178
[TBL] [Abstract][Full Text] [Related]
19. Enhanced anti-neuroblastoma activity of a fenretinide complexed form after intravenous administration.
Carosio R; Pistoia V; Orienti I; Formelli F; Cavadini E; Mangraviti S; Montaldo PG; Ognio E; Emionite L; Zuccari G
J Pharm Pharmacol; 2012 Feb; 64(2):228-36. PubMed ID: 22221098
[TBL] [Abstract][Full Text] [Related]
20. Vorinostat, a histone deacetylase (HDAC) inhibitor, promotes cell cycle arrest and re-sensitizes rituximab- and chemo-resistant lymphoma cells to chemotherapy agents.
Xue K; Gu JJ; Zhang Q; Mavis C; Hernandez-Ilizaliturri FJ; Czuczman MS; Guo Y
J Cancer Res Clin Oncol; 2016 Feb; 142(2):379-87. PubMed ID: 26314218
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
